AR and breast cancer: Preclinical studies detected bicalutamide to inhibit proliferation and increase apoptosis in AR+/ER-negative BC cell lines, and even in the MSL TNBC BC cells, Hs578T and MDA-MB-231, which express relatively low levels of AR (9, 78).